Overview

Price chart · mood · technical indicators

AZN

AstraZeneca PLC ADRstock Healthcare

Drug Manufacturers - General

$183.5130.59%Current Market Mood:Neutral

Market Mood

Price Range (1Y)

$132.32$212.71

Current: $183.51

Idea: EMA

1Y Return

+20.1%

Sharpe 3Y

0.56

Market Comparison

vs Healthcare Sector & Drug Manufacturers - General Industry

AZN

+30.59%

1Y Performance

Healthcare

Sector 1Y

Drug Manufacturers - General

Industry 1Y

Fundamentals

Updated daily after market close

P/E ratio27.86Forward 17.92

EPS (TTM)$6.635.3% YoY

Profit margin17.2%HEALTHCARE

Market cap$286.40BMega cap

Wall Street coverage

$223.79median target· current $151.52 (+47.7%)9 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E: 17.92
PEG ratio: 1.53
P/B: 6.05
P/S (TTM): 4.74
EV/EBITDA: 15.37

Profitability & growth

ROE (TTM): 23.5%
Operating margin: 28.2%
Revenue growth YoY: 12.5%
Dividend yield: 1.7%
Beta: 0.22

Last earnings

Mar 31, 2026 · Estimate $1.27 · Reported $1.29

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About AstraZeneca PLC

Company profile

AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.

Classification

Sector: Healthcare
Industry: Drug Manufacturers - General
Exchange: NASDAQ
Country: USA
Currency: USD

Company profile

HQ: 1 FRANCIS CRICK AVENUE, CAMBRIDGE, UNITED KINGDOM
Fiscal year end: December
Latest quarter: Mar 31, 2026

Market cap$286.40B

Shares outstanding$1.55B

52W high$210.50

52W low$130.04

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer

Overview

AZN

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Astrazeneca Plc $AZN Shares Sold by D.A. Davidson & CO.

FDA advisory committee does not support AstraZeneca’s camizestrant for breast cancer

Employee share plans add 14,807 AstraZeneca (AZN) shares to LSE

AstraZeneca wins FDA AdCom backing for Truqap in prostate cancer

AstraZeneca Prostate Drug Wins FDA Panel Backing As Breast Cancer Candidate Falters

AstraZeneca PLC expected to post earnings of $2.58 a share - Earnings Preview

Update on FDA Advisory Committee vote on camizestrant in combination with a CDK4/6 inhibitor for advanced HR-positive breast cancer

Jennison Associates LLC Has $309.15 Million Holdings in Astrazeneca Plc $AZN

AstraZeneca Is a Buy as More Than 20 Phase III Readouts Loom

FDA panel votes against backing AstraZeneca's breast cancer drug

FDA Panel Votes Against Benefit of Astra’s Breast Cancer Drug

Citi raises AstraZeneca earnings forecast and maintains 'buy' rating ahead of second-half pipeline catalysts

Astrazeneca exercises option for Pinetree’s PTX-299

AstraZeneca takes global rights to an EGFR cancer drug in $25M deal

AstraZeneca PLC 2026 Q1 - Results - Earnings Call Presentation (NYSE:AZN)

AstraZeneca to Invest £300 Million in UK in Boost for Starmer

AstraZeneca (NYSE: AZN) posts Q1 2026 growth and major pipeline deals

AstraZeneca beats profit expectations, keeps annual outlook unchanged

Astrazeneca: Q1 Earnings Snapshot

AstraZeneca Q1 2026 earnings preview

About AstraZeneca PLC

Classification

Company profile

AZN

Market Comparison

AZN Market Analysis

Overview

AZN

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Astrazeneca Plc $AZN Shares Sold by D.A. Davidson & CO.

FDA advisory committee does not support AstraZeneca’s camizestrant for breast cancer

Employee share plans add 14,807 AstraZeneca (AZN) shares to LSE

AstraZeneca wins FDA AdCom backing for Truqap in prostate cancer

AstraZeneca Prostate Drug Wins FDA Panel Backing As Breast Cancer Candidate Falters

AstraZeneca PLC expected to post earnings of $2.58 a share - Earnings Preview

Update on FDA Advisory Committee vote on camizestrant in combination with a CDK4/6 inhibitor for advanced HR-positive breast cancer

Jennison Associates LLC Has $309.15 Million Holdings in Astrazeneca Plc $AZN

AstraZeneca Is a Buy as More Than 20 Phase III Readouts Loom

FDA panel votes against backing AstraZeneca's breast cancer drug

FDA Panel Votes Against Benefit of Astra’s Breast Cancer Drug

Citi raises AstraZeneca earnings forecast and maintains 'buy' rating ahead of second-half pipeline catalysts

Astrazeneca exercises option for Pinetree’s PTX-299

AstraZeneca takes global rights to an EGFR cancer drug in $25M deal

AstraZeneca PLC 2026 Q1 - Results - Earnings Call Presentation (NYSE:AZN)

AstraZeneca to Invest £300 Million in UK in Boost for Starmer

AstraZeneca (NYSE: AZN) posts Q1 2026 growth and major pipeline deals

AstraZeneca beats profit expectations, keeps annual outlook unchanged

Astrazeneca: Q1 Earnings Snapshot

AstraZeneca Q1 2026 earnings preview

About AstraZeneca PLC

Classification

Company profile

AZN

Market Comparison